AnaptysBio Inc
About AnaptysBio Inc
AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States. The company manages financial collaborations for Jemperli, a PD-1 antagonist for various solid tumor indications; and Quimilza, an IL-36R antagonist mAb, which has completed two registration-enabling global Phase 3 trials, and GEMINI-1 and GEMINI-2, evaluating the safety and efficacy of Quimilza in patients with generalized pustular psoriasis. It has a collaboration and exclusive license agreement with GSK plc to develop Jemperli as a monotherapy; and an exclusive license agreement with Vanda Pharmaceuticals Inc. for the development and commercialization of Quimilza. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
- Ticker
- ANAB
- Trading on
- NASDAQ
- ISIN
- -
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Daniel R. Faga
- Headquarters
- 10770 Wateridge Circle, San Diego, CA, United States, 92121
- Employees
- 104
- Website
- anaptysbio.com
Metrics
Analyst Insights & forecasts
Based on information from 8 analysts.
Earnings per share (EPS) forecast
| Q3 • 25 | Q4 • 25 | Q1 • 26 | Q2 • 26 | |
|---|---|---|---|---|
| Actual | $0.52 | $1.58 | -$1.84 | -$0.11 |
| Expected | -$1.25 | $0.93 | -$1.07 | -$0.46 |
| Surprise | 141.60% | 69.89% | -72.26% | 76.09% |
| Beat | Beat | Missed | Current |
Financial Performance
| Q1 • 26 | Q2 • 26 | QoQ growth | |
|---|---|---|---|
| Revenue | $25.6M | $27.5M | 7.56% |
| Net income | $-52.9M | $184M | -447.70% |
| Profit margin | -206.93% | 668.95% | -423.27% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.
FAQs
01How much is a AnaptysBio Inc share?
AnaptysBio Inc shares are currently traded for undefined per share.
02How many shares does AnaptysBio Inc have?
AnaptysBio Inc currently has 29.9M shares.
03Does AnaptysBio Inc pay dividends?
No, AnaptysBio Inc doesn't pay dividends.
04What is AnaptysBio Inc 52 week high?
AnaptysBio Inc 52 week high is $72.36.
05What is AnaptysBio Inc 52 week low?
AnaptysBio Inc 52 week low is $20.18.
06What is the 200-day moving average of AnaptysBio Inc?
AnaptysBio Inc 200-day moving average is $50.73.
07Who is AnaptysBio Inc CEO?
The CEO of AnaptysBio Inc is Daniel R. Faga.
08How many employees AnaptysBio Inc has?
AnaptysBio Inc has 104 employees.
09What is the market cap of AnaptysBio Inc?
The market cap of AnaptysBio Inc is $1.36B.
10What is the P/E of AnaptysBio Inc?
The current P/E of AnaptysBio Inc is null.
11What is the EPS of AnaptysBio Inc?
The EPS of AnaptysBio Inc is -$0.96.
12What is the PEG Ratio of AnaptysBio Inc?
The PEG Ratio of AnaptysBio Inc is 0.
13What do analysts say about AnaptysBio Inc?
According to the analysts AnaptysBio Inc is considered a buy.
